Recardio at J.P. Morgan 2026

San Francisco, January 07, 2026 - Recardio Inc., a late-stage clinical-stage life science company focusing on therapies for cardiovascular diseases, is attending the annual J.P. Morgan Healthcare Conference in San Francisco.

Recardio attending the annual J.P. Morgan Healthcare Week

The company is presenting its technology and clinical therapy program for cardiovascular diseases.

The event is taking place on January 12-15, 2026 in San Francisco, CA.

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

About Recardio

Recardio Inc. is a late-stage clinical biotechnology company focused on developing therapies for cardiometabolic and other diseases through a therapeutic platform, designed for disease modification and regeneration.

The company is located in San Francisco, California, with operations in the USA and Europe.

Recardio’s lead drug candidate, dutogliptin, a DPP-IV inhibitor, has demonstrated efficacy in promoting endogenous disease-modifying cardiac regeneration and supporting tissue repair following cardiac injury. The FDA and EMA have approved the global pivotal Phase 3 HEAL-AMI clinical program in acute myocardial infarction for regulatory authorization in major markets.

In addition, the company is advancing multiple cardiometabolic programs in clinical and preclinical development.

For more information, visit: www.recardio.eu or contact pr@recardio.eu